BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
July 28 2021 - 7:00AM
BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced it
will release its second quarter 2021 financial results on Tuesday,
August 10, 2021 before the open of the U.S. financial markets.
BioXcel’s management team will also host a conference call and
webcast at 8:30 AM EDT to discuss the Company’s financial results
and to provide a general business update.
Conference Call & Webcast
Details |
Date/Time:Domestic:International: |
Tuesday,
August 10, 2021 at 8:30 AM Eastern
Time877-407-2985201-378-4915 |
|
|
The webcast and the accompanying materials will
be accessible* under "Events" on the News & Media page of the
Company's website at www.bioxceltherapeutics.com.
Replay |
Domestic:International: Conference
ID: |
877-660-6853201-612-741513721977 |
|
|
*Replay available through at least August 24, 2021.
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage
biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology. BioXcel's drug re-innovation approach leverages
existing approved drugs and/or clinically validated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BioXcel's two most
advanced clinical development programs are BXCL501, an
investigational, proprietary, orally dissolving thin film
formulation of dexmedetomidine for the treatment of agitation and
opioid withdrawal symptoms, and BXCL701, an investigational, orally
administered, systemic innate immunity activator in development for
the treatment of aggressive forms of prostate cancer and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors. For more information, please visit
www.bioxceltherapeutics.com.
Source: BioXcel Therapeutics, Inc.
Contact Information:
Mary Coleman
Vice President, Investor Relations
BioXcel Therapeutics, Inc.
mcoleman@bioxceltherapeutics.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024